

ClinicalTrials.gov Modernization and How to Provide Your Input

Rebecca J. Williams, Acting Director, ClinicalTrials.gov

March 6, 2020



National Library of Medicine

Agenda

- ClinicalTrials.gov Background
- Modernization Overview
- Request for Information (RFI)
- Provide Your Input

Help guide our efforts to modernize ClinicalTrials.gov. Send us your comments by March 14, 2020.

NIH U.S. National Library of Medicine

ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 331,715 research studies in all 50 states and in 209 countries.

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

IMPORTANT: Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

Before participating in a study, talk to your health care provider and learn about the [risks and potential benefits](#).

Find a study (all fields optional)

Status ⓘ

Recruiting and not yet recruiting studies

All studies

Condition or disease ⓘ (For example: breast cancer)

Other terms ⓘ (For example: NCT number, drug name, investigator name)

Country ⓘ


Search [Advanced Search](#)

[Help](#) [Studies by Topic](#) [Studies on Map](#) [Glossary](#)

Overview

- 330,000+ registrations
- 40,000+ posted results
- 145,000 unique visitors daily
- 215 million page views per month

ClinicalTrials.gov



Abbreviations: AE, adverse event; CFR, Code of Federal Regulations; DoH, Declaration of Helsinki; FDAAA, Food and Drug Administration Amendments Act; FDAMA, Food and Drug Administration Modernization Act; ICMJE, International Committee of Medical Journal Editors; NIH Policy, NIH Policy on the Dissemination of NIH-Funded Clinical Trial Information; NPRM, Notice of Proposed Rulemaking; and WHO, World Health Organization.

Benefits of Comprehensive Registration and Results Reporting

*All contribute to increased
public trust in clinical
research*

- Honor commitment to participants that their contributions will advance science; support enrollment
- Mitigate publication bias
- Advance stewardship and accountability
 - Identify unmet research needs
 - Facilitate complete reporting
 - Avoid unnecessary study duplication
 - Evaluate research integrity
- Support evidence-based medicine

ClinicalTrials.gov Modernization

Ensure ClinicalTrials.gov continues to be a trusted and valued premier public health resource that provides maximum value to the public and serves its mission well into the future.



Who is Modernization For?



Internal

Information specialists, reviewers,
developers

Management, policy, oversight




External

Patients, healthcare providers, and
related organizations

Data submitters (investigators,
sponsors, 3rd party services)

Researchers and journal editors

Aim 1: Collect complete and informative information about clinical studies



Aim 2: Facilitate use of information to help the public and researchers find studies of interest

NIH U.S. National Library of Medicine
ClinicalTrials.gov

Find Studies ▾ About Studies ▾ Submit Studies ▾ Resources ▾ About Site ▾

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world.

Explore 331,715 research studies in all 50 states and in 209 countries.

ClinicalTrials.gov is a resource provided by the U.S. National Library of Medicine.

IMPORTANT: Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our [disclaimer](#) for details.

Before participating in a study, talk to your health care provider and learn about the [risks](#) and [potential benefits](#).

Find a study (all fields optional)

Status ⓘ

Recruiting and not yet recruiting studies

All studies

Condition or disease ⓘ (For example: breast cancer)


Other terms ⓘ (For example: NCT number, drug name, investigator name)

Country ⓘ

[Advanced Search](#)


[Help](#) | [Studies by Topic](#) | [Studies on Map](#) | [Glossary](#)

ClinicalTrials.gov API



National Library of Medicine

ClinicalTrials.gov: Information Scaffold



ClinicalTrials.gov Key Roles and Principles


- Sponsor or investigator
 - Submits study information directly to ClinicalTrials.gov; keeps up-to-date
 - Responsible for safety and validity of study and following applicable laws and regulations
- NLM conducts a limited quality control (QC) review
 - Identifying apparent errors, deficiencies, or inconsistencies
 - Listing does not mean study itself has been evaluated by U.S. government
- Site lists information for many uses, including research participation
 - Participation is an important personal decision; encourage learning about all options and consulting with health care provider and other trusted advisors

Source: Disclaimer <https://clinicaltrials.gov/ct2/about-site/disclaimer>



ClinicalTrials.gov Modernization Overview

Clinical Research Life Cycle |



Current year: Engagement

- Engage with stakeholders to determine and validate approach and specifications
 - Request for Information (RFI) and Public Meeting
- Develop modernization roadmap
- Enhance internal business processes

Future (years 2 – 5): Implementation

- Implement modernization roadmap
 - User testing/evaluation and continue engagement
 - Improvements to support compatibility across clinical trial lifecycle (seamless end-to-end process)
 - Upgrade system infrastructure components

Request for Information (RFI): ClinicalTrials.gov

Modernization

Notice Number:

NOT-LM-20-003

Key Dates

Release Date:

December 30, 2019

Response Date:

March 14, 2020

Related Announcements

None

Issued by

National Library of Medicine (NLM)

Purpose

Introduction

The purpose of this Request for Information is to solicit public input to guide the National Library of Medicine (NLM) in planning infrastructure enhancements aimed at users and submitters of ClinicalTrials.gov as part of a multi-year modernization initiative.

Request for Information (RFI)

- *“... we aim to gather information to help maximize the value of ClinicalTrials.gov to its many users, while continuing to provide essential services to support existing legal and policy requirements.”*

- **March 14 – responses due**



National Library of Medicine

<https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-003.html>

We Request Your Input on These Topics

- 1 Website functionality
- 2 Information submission
- 3 Data standards

Note: RFI not intended to modify existing legal and policy requirements for clinical trial registration and results submission

1. Provide Your Input: Website Functionality

- a. Uses that are not currently supported and examples of other good models
- b. Resources that should be linked from ClinicalTrials.gov and explanation of why such resources are useful
- c. Examples of how you currently use site, what features work well, and what could be improved
- d. Describe whether uses are dependent on wide range of studies or more limited and explain any limiting criteria that are useful to you

POLL: What is the primary task you are trying to accomplish using ClinicalTrials.gov?

- A. Register a trial or submit results information
- B. Search for trials for myself or someone else
- C. Conduct research on clinical trials, such as a landscape analysis or systematic review
- D. None of the above

ClinicalTrials.gov Users by Role

42% Patients and Caregivers, including:

- 24% Patient
- 8% Family/friend of patient
- 5% Healthcare provider
- 5% Healthy person

9% Not Categorized (“Other”)

49% Researchers and Others, including:


- 26% Scientist/researcher
- 8% Clinical research support (e.g., regulatory affairs)
- 6% Clinical trials staff
- 5% Student/educator
- 3% Medical communications
- 2% Librarian or information professional
- <1% IRB or ethics committee member

Source: ClinicalTrials.gov Qualtrics Survey Data: 1 July 2019 – 31 December 2019 (n=3,399)



Recent Website Updates

- Options to improve first search precision
 - A. Recruitment status
 - B. Location
- Research participation resources and disclaimer
 - Help people learn what ClinicalTrials.gov listing does and doesn't mean
- Search results options; filters and custom display



Beta API (Application Programming Interface)

- Supports 3rd party electronic use of ClinicalTrials.gov content
- Over 300 search fields available (current API has 24 key fields)
- Formats: XML, JSON, SVI, tree
- Query and Info URLs
- Documentation and interactive training demos
- <https://clinicaltrials.gov/api/gui>

U.S. National Library of Medicine
ClinicalTrials.gov API **API Home (BETA)**

The ClinicalTrials.gov BETA application programming interface (API) is being made available for beta testing and feedback. After further development, it is intended to replace the current API.
If you are looking for information about clinical studies, please visit [ClinicalTrials.gov](https://clinicaltrials.gov).

ClinicalTrials.gov API site

The ClinicalTrials.gov application programming interface (API) provides a toolbox for programmers and other technical users to use to access all posted information on ClinicalTrials.gov study records data. The API is designed for encoding simple and complex search expressions and parameters in URLs. Clicking on query URLs retrieves study records from ClinicalTrials.gov. Use of ClinicalTrials.gov data is subject to these [Terms and Conditions](#).

If you are looking for information about clinical studies, please visit [ClinicalTrials.gov](https://clinicaltrials.gov).

Documentation

Link	Description
API URLs	List of info URLs for accessing information about the API and query URLs with parameters.
Query URL Response	Description of information returned by query URLs.

Interactive Demonstrations

Use the following demonstrations to explore and develop the three types of [query URLs](#) available for accessing different levels of API data from [ClinicalTrials.gov](https://clinicaltrials.gov).

Query URL Type	Description	Example
Full Studies	Retrieves all content from the first study record returned for a submitted query by default. Returns up to 100 study records per query when the minimum rank and maximum rank parameters are set in a query URL and up to 100,000 records using the Full Studies interactive demonstration.	https://ClinicalTrials.gov/api/query/full_studies?expr=heart+attack
Study Fields	Retrieves the value of one or more fields from up to 100,000 study records returned for a submitted query by default. Returns up to 1,000 study records per query when the minimum rank and maximum rank parameters are set in a query URL and up to 100,000 records using the Study Fields interactive demonstration.	https://ClinicalTrials.gov/api/query/study_fields?expr=heart+attack&fields=NCTID,Condition,NotesTitle
Field Values	Retrieves a unique list of values for one study field from all study records returned for a submitted query.	https://ClinicalTrials.gov/api/query/field_values?expr=heart+attack&field=Condition

CURRENT API VERSION 1.04.04 [SHOW FULL LOG](#)

[Contact Us](#) [Privacy](#) [Accessibility](#) [Freedom of Information Act](#) [USA.gov](#)
U.S. National Library of Medicine | U.S. National Institutes of Health | U.S. Department of Health and Human Services

Content of ClinicalTrials.gov (as of Jan 10, 2020)

Study and Intervention Type		Number Registered Studies (% Total)	No. Studies with Posted Results (% Total) ***
Total Records		326,612	40,841
Interventional Studies		257,482 (79%)	38,361 (94%)
Type of Intervention*	Drug or biologic	144,503	29,807
	Behavioral, other	83,013	7,279
	Surgical procedure	27,089	2,068
	Device**	32,977	5,063
Observational Studies		67,671 (21%)	2,480 (6%)
Expanded Access		603	N/A

*A study may include more than one type of intervention, meaning that a single study may be counted more than once.


**A total of 856 applicable device clinical trials have been submitted as "delayed posting" under FDAAA/Part 11 (i.e., in "lockbox") and are not included in the counts of trials.

***Results are required to be submitted only for certain studies.

Source: ClinicalTrials.gov Trends, Charts, Maps (Jan 10, 2020) <https://clinicaltrials.gov/ct2/resources/trends>



Location of Registered Studies (as of Jan 10, 2020)



Location of Study Sites	Number Registered Studies (% Total)
United States (U.S.) only	110,661 (34%)
Both U.S. and non-U.S.	17,051 (5%)
Non-U.S. Only	160,085 (49%)
Not provided	38,815 (12%)
Total	326,612 (100%)

Source: ClinicalTrials.gov Trends, Charts, Maps (Jan 10, 2020) <https://clinicaltrials.gov/ct2/resources/trends>



2. Provide Your Input: Information Submission

- a. Steps in submission process that would most benefit from improvements
- b. Opportunities for alignment with organization processes, such as interoperability with clinical trial management software or tools
- c. Novel or emerging methods for enhancing quality and submitted content and displayed on ClinicalTrials.gov
- d. Informational materials that would make process easier
- e. Ways to credit, incentivize, or recognize efforts of individuals and organizations submitting complete, accurate, and timely information

POLL: Have you registered a study or submitted results information to ClinicalTrials.gov?

- A. Yes, registration only
- B. Yes, registration and results information
- C. No, no experience with registration or results submission
- D. No, not personally but a member of my team has
- E. Yes, but we use a third party to help ensure information is submitted to ClinicalTrials.gov

Basics of Registration Information Submission

ClinicalTrials.gov PRS

Protocol Registration and Results System


- Interactive data entry or automated upload
- Anyone can enter data, but “responsible party” must submit
- Content reflects:
 - Legal requirements
 - International standards
 - Good reporting practices
- NIH grant application aligns with subset of content

Help Definitions

* Organization's Unique Protocol ID:

* Brief Title: [Special Characters](#)

[*] Acronym: (if any)
If specified, will be included at end of Brief Title in parentheses.

 * Study Type:

- Interventional** (or clinical trial) — participants assigned to intervention(s) based on a protocol
- Observational** participants not assigned to intervention(s) based on a protocol; typically in context of routine care
- Expanded Access** availability of an experimental drug or device outside of a clinical trial protocol

* Required
* § Required if Study Start Date is on or after January 18, 2017
[*] Conditionally required (see Definitions)

Basics of Registration Information Submission

ClinicalTrials.gov PRS

Protocol Registration and Results System

- Structure supports:
 - Complete reporting
 - Efficient quality review
 - Consistent data display
 - Detailed search and integration of other NLM resources
- Aligns with good reporting practices (CONSORT)

Edit Baseline Measure

[Help](#) [Definitions](#)

* Study-Specific Baseline Measure Title:

Baseline Measure Description:

	Remuverol	Placebo	Total
Overall Number of Baseline Participants:	101	99	200
Baseline Analysis Population Description:			

* Measure Type:

* Measure of Dispersion:

	101 participants <input type="button" value="Edit"/>	99 participants <input type="button" value="Edit"/>	200
Mean	<input type="text" value="77.03"/>	<input type="text" value="78.53"/>	<input type="text" value="77.77"/>
Standard Deviation	<input type="text" value="14.38"/>	<input type="text" value="13.56"/>	<input type="text" value="14.00"/>

+ Add Row

* Unit of Measure:

Quality Control Review Process and Volume

- Quality control review focused on identifying apparent errors, deficiencies, or inconsistencies
- Review all registration study records < 5 days
 - ~1,200 new registration records per week (includes new records and previously reviewed records that did not meet QC review criteria)
 - ~6,600 updated registration records per week
- Review all results study records < 25 days
 - ~280 new results records per week (includes new records and previously reviewed records that did not meet QC review criteria)
 - ~140 updated results records per week

PRS: Example of Automated Validation Rule

ERROR – Information is missing

Edit	Arm/Group Title	Remuverol	Placebo	Total
	▶ Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...	
Edit	Overall Number of Baseline Participants	⊘ ERROR : The Overall Number of Baseline Participants has not been entered.	99	
	▶ Baseline Analysis Population Description			

CORRECTED – Missing information added

Edit	Arm/Group Title	Remuverol	Placebo	Total
	▶ Arm/Group Description	Participants received Remuverol 15 ...	Participants received Remuverol pla...	
Edit	Overall Number of Baseline Participants	101	99	200
	▶ Baseline Analysis Population Description			

Quality Control Review Example

Baseline Measures – Example

	Drug X
GOG Performance Status [units: participants]	
0	48
1	27
2	4

Baseline Measures – Example Corrected

	Drug X
Gynecological Oncology Group (GOG) Performance Status [units: participants]	
0 – Fully Active	48
1 – Restricted Strenuous Activity, Ambulatory	27
2 – Ambulatory, Difficulty Walking	4
3 – Limited Self-Care, Partly Confined to Bed	0
4 – Completely Disabled, No Self-Care	0

5-point, ordinal scale specifying patient's ability to perform activities from 0 (fully active) to 4 (completely disabled, no self-care)

Results Submission “Success:” Industry and Non-Industry Orgs

Sample: initial results submitted \geq 1 May 2017 and QC reviewed \leq 30 Sept 2018

Org Type	# Orgs	Cycle 1		Cycle 2	
		#Records	% Success	#Records	% Success
Industry	572	2780	31	2140	77
Non-Industry	777	3486	17	2359	63
All	1349	6266	23	4499	70

$$\%Success = 100\% \times \frac{\# \text{ Records with no Major Issues}}{\# \text{ Total Record Submissions}}$$

Source: N Engl J Med 2019; 381:1966-74. DOI: 10.1056/NEJMSr1907644

Top 5 Major Issues for Results

- 1** Invalid or inconsistent unit of measure
- 2** Insufficient information about a scale used for assessment
- 3** Inconsistency between information in different parts of record
- 4** Written results or conclusions
- 5** Unclear baseline or outcome measure

PRS Guided Tutorials

- Launched August 2019
- Access on ClinicalTrials.gov or PRS
- Results submission content first
 - Registration content expected in March 2020
- Collecting feedback via survey
 - <https://bit.ly/2N1mMHV>
 - Further evaluation underway

ClinicalTrials.gov PRS
Protocol Registration and Results System
PRS Guided Tutorials (Beta)

10%

- Introduction
- Preparing to Enter Results
- Entering Participant Flow Information**
- Entering Baseline Characteristics Information
- Entering Outcome Measure and Statistical Analysis Information
- Entering Adverse Event Information
- Entering Limitations and Caveats
- Entering More Information: Certain Agreements and

this information is translated is shown here in the CONSORT Flow Diagram to Participant Flow Table Crosswalk.

CONSORT Diagram to Participant Flow Table Crosswalk

Parallel Study Design Example CONSORT Flow Diagram

ClinicalTrials.gov Participant Flow Table

Participant Flow	Number of Participants
Eligible	100
Randomized	100
Discontinued	10
Completed	90

Resources

Before entering information in the Participant Flow module, use these resources to help you gather and organize the information you will need:


- [Participant Flow Data Preparation Checklist](#)
- [Participant Flow Template](#)
- [Results Data Element Definitions—Participant Flow](#)

You can also refer to the [Results Quality Control Review Criteria](#), which will help you

3. Provide Your Input: Data Standards

- a. Input on ways to balance use of standards while also retaining flexibility to accurately reflect content of study protocol and statistical analysis plan
- b. Name specific standards and explain how they may be useful in improving data quality, enabling reuse of data to reduce reporting burden, or improving consistency and management of data on ClinicalTrials.gov

Clinical Trial Lifecycle Opportunities



POLL: Which is most important to you to be addressed first with improved features? (Pick your top TWO)

- A. Website functionality - enhance public site features for finding and managing trials of interest
- B. Information submission - credit, incentivize, or recognize efforts of submitting timely information
- C. Information submission – enhance interoperability with existing software applications or tools
- D. Information submission - support submission quality with more automated support
- E. Information submission - provide more informational materials and resources
- F. Data standards – enhance submission or reuse of clinical trial information

Submitting Feedback

- “The Insider’s Guide to Effective Commenting on NIH Policies” (from the NIH Office of Science Policy)
 - Be specific
 - Provide data
 - Answer the questions
 - Include new ideas
 - Emphasize what matters most
- Reference: <https://osp.od.nih.gov/2018/06/08/insides-guide-effective-commenting-nih-policies/>

Submitting Feedback - Reminders

- **March 14, 2020** is the deadline for submitting feedback using web-based form accessible from the RFI:
 - <https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-003.html>
- Submitted responses will be posted publicly without change after the close of the comment period.
 - Do not include proprietary, classified, confidential, or sensitive information
 - Do not include personally identifiable information you do not wish to be made public
- RFI not intended to modify existing legal and policy requirements for clinical trial registration and results submission

Public Meeting – April 30, 2020

- We will share a summary of the RFI responses and initial interpretation of themes and priorities
- Opportunity for further discussion and clarification of topics
- Hosted at the NIH in Bethesda, MD and also available by videocast
- More details on how to register
 - Modernization information page: <https://clinicaltrials.gov/ct2/about-site/modernization>

Stay up to date with *Hot Off the PRS!*

- E-mail bulletin
- Provides timely updates for PRS users on new information about the PRS and ClinicalTrials.gov
- Sign up: <https://bit.ly/33qcZBb>

ClinicalTrials.gov *PRS*
Protocol Registration and Results System

Hot Off the PRS!

Latest Release and Updates



Having trouble viewing this email? [View it as a Web page.](#)

SHARE

What's New?

Celebrating 20 Years of ClinicalTrials.gov and Looking to the Future

ClinicalTrials.gov acting director Rebecca Williams, PharmD, MPH, has authored a [guest post](#) on the National Library of Medicine [Musings from the Mezzanine](#) blog. Read her post to learn more about opportunities to engage with us to enrich and modernize ClinicalTrials.gov.

ClinicalTrials.gov Modernization RFI and Webinar

As part of the ClinicalTrials.gov Modernization initiative, we have issued a [Request for Information](#) (RFI) to solicit comments on the following topics: website functionality, information submission processes, and use of data standards. To learn more about the initiative, the RFI, and how to share your feedback, please [register](#) to join the webinar on January 22, 3:30-4 pm ET.

A recording of the webinar and slides will be made available for those who cannot attend live.



NLM Wants to Hear From You!



Now

Learn more
about Modernization

<https://clinicaltrials.gov/ct2/about-site/modernization>



14 Mar 2020

Submit comments to
the RFI *before*
March 14, 2020

<https://grants.nih.gov/grants/guide/notice-files/NOT-LM-20-003.html>



30 Apr 2020

Save the date –
Public meeting to learn
about RFI comments

https://events-support.com/events/ClinicalTrials-gov_Modernization_Public_Meeting

Thank You

**Questions? Submit to the ClinicalTrials.gov Information Team
National Library of Medicine
register@clinicaltrials.gov**

ClinicalTrials.gov Modernization Information

<https://clinicaltrials.gov/ct2/about-site/modernization>